Table 2.
Patient-level prevalence of guideline adherence and potential misuse outcomes.
| Patient adherence prevalence | Total (N = 1546), n (%) | Site 1 (n = 271), n (%) | Site 2 (n = 186), n (%) | Site 3 (n = 1089), n (%) | P* |
|---|---|---|---|---|---|
| Opioid treatment agreement† | 679 (44) | 122 (45) | 91 (49) | 466 (43) | 0.27 |
| Urine drug screen‡ | 861 (56) | 65 (24) | 68 (37) | 728 (67) | <0.0001 |
| Early refills§ | 555 (36) | 105 (39) | 63 (34) | 387 (36) | 0.51 |
*
χ2 test for categorical variables and analysis of variance for continuous variables across 3 sites.
†
Electronic health record documentation of an opioid treatment agreement ever.
‡
Urine Drug Screen in the past 12 mo.
§
An opioid prescription written 7 to 25 d after the previous prescription for the same medication.